Antigen-specific tolerization approaches in multiple sclerosis

Bibliography

• Steinman L. Inverse vaccination, the opposite of jenner's concept, for therapy of autoimmunity. J Intern Med 2010;267(5):441-51
   PubMed Web of Science ®Google Scholar
• Dolgin E. The inverse of immunity. Nat Med 2010;16(7):740-3
   PubMed Web of Science ®Google Scholar
• Lutterotti A, Sospedra M, Martin R. Antigen-specific therapies in ms - current concepts and novel approaches. J Neurol Sci 2008;274(1-2):18-22
   PubMed Web of Science ®Google Scholar
• Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005;23:683-747
   PubMed Web of Science ®Google Scholar
• Goverman JM. Immune tolerance in multiple sclerosis. Immunol Rev 2011;241(1):228-40
   PubMedGoogle Scholar
• Schwartz RH. T cell anergy. Annu Rev Immunol 2003;21:305-34
   PubMed Web of Science ®Google Scholar
• Jenkins MK, Mueller D, Schwartz RH, et al. Induction and maintenance of anergy in mature t cells. Adv Exp Med Biol 1991;292:167-76
   PubMedGoogle Scholar
• Jenkins MK, Schwartz RH. Antigen presentation by chemically modified splenocytes induces antigen-specific t cell unresponsiveness in vitro and in vivo. J Exp Med 1987;165(2):302-19
   PubMed Web of Science ®Google Scholar
• Krummel MF, Allison JP. Ctla-4 engagement inhibits il-2 accumulation and cell cycle progression upon activation of resting t cells. J Exp Med 1996;183(6):2533-40
   PubMed Web of Science ®Google Scholar
• Walunas TL, Lenschow DJ, Bakker CY, et al. Ctla-4 can function as a negative regulator of t cell activation. Immunity 1994;1(5):405-13
   PubMed Web of Science ®Google Scholar
• Fife BT, Bluestone JA. Control of peripheral t-cell tolerance and autoimmunity via the ctla-4 and pd-1 pathways. Immunol Rev 2008;224:166-82
   PubMed Web of Science ®Google Scholar
• Mueller DL. Mechanisms maintaining peripheral tolerance. Nat Immunol 2010;11(1):21-7
   PubMed Web of Science ®Google Scholar
• Alderson MR, Tough TW, Davis-Smith T, et al. Fas ligand mediates activation-induced cell death in human t lymphocytes. J Exp Med 1995;181(1):71-7
   PubMed Web of Science ®Google Scholar
• Kabelitz D, Janssen O. Antigen-induced death of t-lymphocytes. Front Biosci 1997;2:d61-77
   PubMedGoogle Scholar
• von Boehmer H, Melchers F. Checkpoints in lymphocyte development and autoimmune disease. Nat Immunol 2010;11(1):14-20
   PubMed Web of Science ®Google Scholar
• Rudensky AY. Regulatory t cells and foxp3. Immunol Rev 2011;241(1):260-8
   PubMedGoogle Scholar
• Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory t cells and immune tolerance. Cell 2008;133(5):775-87
   PubMed Web of Science ®Google Scholar
• von Boehmer H, Daniel C. Therapeutic opportunities for manipulating t(reg) cells in autoimmunity and cancer. Nat Rev Drug Discov 2013;12(1):51-63
   PubMed Web of Science ®Google Scholar
• Miller SD, Turley DM, Podojil JR. Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease. Nat Rev Immunol 2007;7(9):665-77
   PubMed Web of Science ®Google Scholar
• Weiner HL, Friedman A, Miller A, et al. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol 1994;12:809-37
   PubMed Web of Science ®Google Scholar
• Faria AM, Weiner HL. Oral tolerance. Immunol Rev 2005;206:232-59
   PubMed Web of Science ®Google Scholar
• Weiner HL, Mackin GA, Matsui M, et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 1993;259(5099):1321-4
   PubMed Web of Science ®Google Scholar
• Warren KG, Catz I, Ferenczi LZ, Krantz MJ. Intravenous synthetic peptide mbp8298 delayed disease progression in an hla class ii-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment. Eur J Neurol 2006;13(8):887-95
   PubMed Web of Science ®Google Scholar
• Warren KG, Catz I, Wucherpfennig KW. Tolerance induction to myelin basic protein by intravenous synthetic peptides containing epitope p85 vvhffknivtp96 in chronic progressive multiple sclerosis. J Neurol Sci 1997;152(1):31-8
   PubMed Web of Science ®Google Scholar
• Freedman MS, Bar-Or A, Oger J, et al. A Phase III study evaluating the efficacy and safety of mbp8298 in secondary progressive ms. Neurology 2011;77(16):1551-60
   PubMed Web of Science ®Google Scholar
• Goodkin DE, Shulman M, Winkelhake J, et al. A Phase I trial of solubilized dr2:mbp84-102 (ag284) in multiple sclerosis. Neurology 2000;54(7):1414-20
   PubMed Web of Science ®Google Scholar
• Yadav V, Bourdette DN, Bowen JD, et al. Recombinant t-cell receptor ligand (rtl) for treatment of multiple sclerosis: a double-blind, placebo-controlled, Phase I, dose-escalation study. Autoimmune Dis 2012;2012:954739
   PubMedGoogle Scholar
• Vandenbark AA, Rich C, Mooney J, et al. Recombinant tcr ligand induces tolerance to myelin oligodendrocyte glycoprotein 35-55 peptide and reverses clinical and histological signs of chronic experimental autoimmune encephalomyelitis in hla-dr2 transgenic mice. J Immunol 2003;171(1):127-33
   PubMed Web of Science ®Google Scholar
• Available from: http://Www.Apitope.Com/pipeline/ms.Html
   Google Scholar
• Walczak A, Siger M, Ciach A, et al. Transdermal application of myelin peptides in multiple sclerosis treatment. JAMA Neurol 2013 Sep 1;70(9):1105-9
   PubMed Web of Science ®Google Scholar
• Jurynczyk M, Walczak A, Jurewicz A, et al. Immune regulation of multiple sclerosis by transdermally applied myelin peptides. Ann Neurol 2010;68(5):593-601
   PubMed Web of Science ®Google Scholar
• Nicholson LB, Greer JM, Sobel RA, et al. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity 1995;3(4):397-405
   PubMed Web of Science ®Google Scholar
• Windhagen A, Scholz C, Hollsberg P, et al. Modulation of cytokine patterns of human autoreactive t cell clones by a single amino acid substitution of their peptide ligand. Immunity 1995;2(4):373-80
   PubMed Web of Science ®Google Scholar
• Bielekova B, Goodwin B, Richert N, et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a Phase II clinical trial with an altered peptide ligand. Nat Med 2000;6(10):1167-75
   PubMed Web of Science ®Google Scholar
• Crowe PD, Qin Y, Conlon PJ, Antel JP. Nbi-5788, an altered mbp83-99 peptide, induces a t-helper 2-like immune response in multiple sclerosis patients. Ann Neurol 2000;48(5):758-65
   PubMed Web of Science ®Google Scholar
• Kappos L, Comi G, Panitch H, et al. Induction of a non-encephalitogenic type 2 t helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized Phase II trial. The altered peptide ligand in relapsing ms study group. Nat Med 2000;6(10):1176-82
   PubMed Web of Science ®Google Scholar
• Ho PP, Fontoura P, Platten M, et al. A suppressive oligodeoxynucleotide enhances the efficacy of myelin cocktail/il-4-tolerizing DNA vaccination and treats autoimmune disease. J Immunol 2005;175(9):6226-34
   PubMed Web of Science ®Google Scholar
• Ho PP, Fontoura P, Ruiz PJ, et al. An immunomodulatory gpg oligonucleotide for the treatment of autoimmunity via the innate and adaptive immune systems. J Immunol 2003;171(9):4920-6
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Vollmer T, Antel J, et al. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled Phase I/II trial. Arch Neurol 2007;64(10):1407-15
   PubMed Web of Science ®Google Scholar
• Garren H, Robinson WH, Krasulova E, et al. Phase II trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. Ann Neurol 2008;63(5):611-20
   PubMed Web of Science ®Google Scholar
• Papadopoulou A, von Felten S, Traud S, et al. Evolution of ms lesions to black holes under DNA vaccine treatment. J Neurol 2012;259(7):1375-82
   PubMed Web of Science ®Google Scholar
• Roep BO, Solvason N, Gottlieb PA, et al. Plasmid-encoded proinsulin preserves c-peptide while specifically reducing proinsulin-specific cd8+ t cells in type 1 diabetes. Sci Transl Med 2013;5(191):191ra182
   Web of Science ®Google Scholar
• Correale J, Lund B, McMillan M, et al. T cell vaccination in secondary progressive multiple sclerosis. J Neuroimmunol 2000;107(2):130-9
   PubMed Web of Science ®Google Scholar
• Hafler DA, Cohen I, Benjamin DS, Weiner HL. T cell vaccination in multiple sclerosis: a preliminary report. Clin Immunol Immunopathol 1992;62(3):307-13
   PubMedGoogle Scholar
• Hermans G, Medaer R, Raus J, Stinissen P. Myelin reactive t cells after t cell vaccination in multiple sclerosis: cytokine profile and depletion by additional immunizations. J Neuroimmunol 2000;102(1):79-84
   PubMed Web of Science ®Google Scholar
• Medaer R, Stinissen P, Truyen L, et al. Depletion of myelin-basic-protein autoreactive t cells by t-cell vaccination: pilot trial in multiple sclerosis. Lancet 1995;346(8978):807-8
   PubMed Web of Science ®Google Scholar
• Van der Aa A, Hellings N, Medaer R, et al. T cell vaccination in multiple sclerosis patients with autologous csf-derived activated t cells: results from a pilot study. Clin Exp Immunol 2003;131(1):155-68
   PubMed Web of Science ®Google Scholar
• Zhang J, Medaer R, Stinissen P, et al. Mhc-restricted depletion of human myelin basic protein-reactive t cells by t cell vaccination. Science 1993;261(5127):1451-4
   PubMed Web of Science ®Google Scholar
• Fox E, Wynn D, Cohan S, et al. A randomized clinical trial of autologous t-cell therapy in multiple sclerosis: subset analysis and implications for trial design. Mult Scler 2012;18(6):843-52
   PubMed Web of Science ®Google Scholar
• Loftus B, Newsom B, Montgomery M, et al. Autologous attenuated t-cell vaccine (tovaxin) dose escalation in multiple sclerosis relapsing-remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapies. Clin Immunol 2009;131(2):202-15
   PubMed Web of Science ®Google Scholar
• Achiron A, Lavie G, Kishner I, et al. T cell vaccination in multiple sclerosis relapsing-remitting nonresponders patients. Clin Immunol 2004;113(2):155-60
   PubMed Web of Science ®Google Scholar
• Karussis D, Shor H, Yachnin J, et al. T cell vaccination benefits relapsing progressive multiple sclerosis patients: a randomized, double-blind clinical trial. PLoS ONE 2012;7(12):e50478
   PubMed Web of Science ®Google Scholar
• Vandenbark AA, Chou YK, Whitham R, et al. Treatment of multiple sclerosis with t-cell receptor peptides: results of a double-blind pilot trial. Nat Med 1996;2(10):1109-15
   PubMed Web of Science ®Google Scholar
• Bourdette DN, Edmonds E, Smith C, et al. A highly immunogenic trivalent t cell receptor peptide vaccine for multiple sclerosis. Mult Scler 2005;11(5):552-61
   PubMed Web of Science ®Google Scholar
• Vandenbark AA, Culbertson NE, Bartholomew RM, et al. Therapeutic vaccination with a trivalent t-cell receptor (tcr) peptide vaccine restores deficient foxp3 expression and tcr recognition in subjects with multiple sclerosis. Immunology 2008;123(1):66-78
   PubMed Web of Science ®Google Scholar
• Braley-Mullen H, Tompson JG, Sharp GC, Kyriakos M. Suppression of experimental autoimmune thyroiditis in guinea pigs by pretreatment with thyroglobulin-coupled spleen cells. Cell Immunol 1980;51(2):408-13
   PubMed Web of Science ®Google Scholar
• Dua HS, Gregerson DS, Donoso LA. Inhibition of experimental autoimmune uveitis by retinal photoreceptor antigens coupled to spleen cells. Cell Immunol 1992;139(2):292-305
   PubMed Web of Science ®Google Scholar
• Fife BT, Guleria I, Gubbels Bupp M, et al. Insulin-induced remission in new-onset nod mice is maintained by the pd-1-pd-l1 pathway. J Exp Med 2006;203(12):2737-47
   PubMed Web of Science ®Google Scholar
• Gregorian SK, Clark L, Heber-Katz E, et al. Induction of peripheral tolerance with peptide-specific anergy in experimental autoimmune neuritis. Cell Immunol 1993;150(2):298-310
   PubMed Web of Science ®Google Scholar
• Karpus WJ, Pope JG, Peterson JD, et al. Inhibition of theiler's virus-mediated demyelination by peripheral immune tolerance induction. J Immunol 1995;155(2):947-57
   PubMed Web of Science ®Google Scholar
• Kennedy KJ, Smith WS, Miller SD, Karpus WJ. Induction of antigen-specific tolerance for the treatment of ongoing, relapsing autoimmune encephalomyelitis: A comparison between oral and peripheral tolerance. J Immunol 1997;159(2):1036-44
   PubMed Web of Science ®Google Scholar
• Kennedy MK, Tan LJ, Dal Canto MC, et al. Inhibition of murine relapsing experimental autoimmune encephalomyelitis by immune tolerance to proteolipid protein and its encephalitogenic peptides. J Immunol 1990;144(3):909-15
   PubMed Web of Science ®Google Scholar
• Miller SD, Claman HN. The induction of hapten-specific t cell tolerance by using hapten-modified lymphoid cells. I. Characteristics of tolerance induction. J Immunol 1976;117(5 Pt 1):1519-26
   PubMed Web of Science ®Google Scholar
• Miller SD, Tan LJ, Kennedy MK, Dal Canto MC. Specific immunoregulation of the induction and effector stages of relapsing eae via neuroantigen-specific tolerance induction. Ann N Y Acad Sci 1991;636:79-94
   PubMed Web of Science ®Google Scholar
• Miller SD, Wetzig RP, Claman HN. The induction of cell-mediated immunity and tolerance with protein antigens coupled to syngeneic lymphoid cells. J Exp Med 1979;149(3):758-73
   PubMed Web of Science ®Google Scholar
• Pope L, Paterson PY, Miller SD. Antigen-specific inhibition of the adoptive transfer of experimental autoimmune encephalomyelitis in lewis rats. J Neuroimmunol 1992;37(3):177-89
   PubMed Web of Science ®Google Scholar
• Tan LJ, Kennedy MK, Dal Canto MC, Miller SD. Successful treatment of paralytic relapses in adoptive experimental autoimmune encephalomyelitis via neuroantigen-specific tolerance. J Immunol 1991;147(6):1797-802
   PubMed Web of Science ®Google Scholar
• Turley DM, Miller SD. Peripheral tolerance induction using ethylenecarbodiimide-fixed apcs uses both direct and indirect mechanisms of antigen presentation for prevention of experimental autoimmune encephalomyelitis. J Immunol 2007;178(4):2212-20
   PubMed Web of Science ®Google Scholar
• Kohm AP, Turley DM, Miller SD. Targeting the tcr: T-cell receptor and peptide-specific tolerance-based strategies for restoring self-tolerance in cns autoimmune disease. Int Rev Immunol 2005;24(5-6):361-92
   PubMed Web of Science ®Google Scholar
• Smarr CB, Hsu CL, Byrne AJ, et al. Antigen-fixed leukocytes tolerize th2 responses in mouse models of allergy. J Immunol 2011;187(10):5090-8
   PubMed Web of Science ®Google Scholar
• Lutterotti A, Yousef S, Sputtek A, et al. Antigen-specific tolerance by autologous myelin peptide-coupled cells – a Phase I trial in multiple sclerosis. Sci Transl Med 2013;5(188):188ra75
   PubMedGoogle Scholar
• Getts DR, Turley DM, Smith CE, et al. Tolerance induced by apoptotic antigen-coupled leukocytes is induced by pd-l1 + and il-10-producing splenic macrophages and maintained by t regulatory cells. J Immunol 2011;187(5):2405-17
   PubMed Web of Science ®Google Scholar
• Raiotach-Regue D, Grau-Lopez L, Naranjo-Gomez M, et al. Stable antigen-specific t-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients. Eur J Immunol 2012;42(3):771-82
   PubMed Web of Science ®Google Scholar
• Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007;17(2):210-18
   PubMed Web of Science ®Google Scholar
• Goebels N, Hofstetter H, Schmidt S, et al. Repertoire dynamics of autoreactive t cells in multiple sclerosis patients and healthy subjects: epitope spreading versus clonal persistence. Brain 2000;123(Pt 3):508-18
   PubMedGoogle Scholar
• Tuohy VK, Yu M, Weinstock-Guttman B, Kinkel RP. Diversity and plasticity of self recognition during the development of multiple sclerosis. J Clin Invest 1997;99(7):1682-90
   PubMed Web of Science ®Google Scholar
• Tuohy VK, Yu M, Yin L, et al. Regression and spreading of self-recognition during the development of autoimmune demyelinating disease. J Autoimmun 1999;13(1):11-20
   PubMed Web of Science ®Google Scholar
• McRae BL, Vanderlugt CL, Dal Canto MC, Miller SD. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J Exp Med 1995;182(1):75-85
   PubMed Web of Science ®Google Scholar
• Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2002;2(2):85-95
   PubMed Web of Science ®Google Scholar
• Bielekova B, Sung MH, Kadom N, et al. Expansion and functional relevance of high-avidity myelin-specific cd4+ t cells in multiple sclerosis. J Immunol 2004;172(6):3893-904
   PubMed Web of Science ®Google Scholar
• Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364(9451):2106-12
   PubMed Web of Science ®Google Scholar
• Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358(7):676-88
   PubMed Web of Science ®Google Scholar
• Srivastava R, Aslam M, Kalluri SR, et al. Potassium channel kir4.1 as an immune target in multiple sclerosis. N Engl J Med 2012;367(2):115-23
   PubMed Web of Science ®Google Scholar
• McFarland HF, Frank JA, Albert PS, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992;32(6):758-66
   PubMed Web of Science ®Google Scholar
• Miller DH, Barkhof F, Nauta JJ. Gadolinium enhancement increases the sensitivity of mri in detecting disease activity in multiple sclerosis. Brain 1993;116(Pt 5):1077-94
   PubMed Web of Science ®Google Scholar